✉news HealthMedicine first seen 14 h ago, last 11 h ago, peak #37

Analysts Argue WILLOW Trial Endpoint, Not Enpatoran, Failed

Original: The WILLOW Trial Didn’t Fail Enpatoran. The Endpoint Did.

Commentary around Merck KGaA's enpatoran is challenging the framing of the WILLOW trial results, arguing the drug was not proven ineffective but that the trial's chosen endpoint failed to capture the treatment effect. The piece says the outcome measure, not the therapy itself, is what fell short, reigniting debate over how lupus clinical trials are designed and judged.

Why now: The trial's results are fresh news and the contrarian endpoint argument is fueling debate among clinicians and investors.

EnpatoranWILLOW trialMerck KGaAlupus

Open on news →

Rank over time, top of the chart is #1. 3 snapshots from 14 h ago to 11 h ago.

Evidence

• The WILLOW Trial Didn’t Fail Enpatoran. The Endpoint Did. · The Clinical Trial Vanguard

API: https://socialmediatrends-api.osmike.com/v1/trends/208195